Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse™ family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology. The agreement focuses on Japan, where Fujirebio's Lumipulse product line is placed in a significant number of hospitals and clinical reference labs and will be extended with future placements of Lumipulse platforms in other markets worldwide.

The PCT assay is available worldwide on several different laboratory instruments from strategic license partners. In Europe, the PCT test, which has been the gold standard for the early detection of sepsis in critically ill patients, helps doctors to make an early determination whether an infection is bacterial or viral and quickly provides information on the severity of a patient's condition for appropriate treatment and therapy monitoring. In Japan, the PCT assay is used in patients suspected of having sepsis. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management.

"This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient's outcome," said Marc Tremblay, president of Thermo Fisher Scientific's Clinical Diagnostics business. "Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost-savings."

Source: Thermo Fisher Scientific

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, April 30). Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing". News-Medical. https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx. (accessed April 25, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center